NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations
Movement Disorders · 2024-11 · 39 (11) · 2039-2048
DOI: 10.1002/mds.29902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 16.09.2024. Verfasst von Sara Bandres-Ciga und 34 weiteren Autor:innen. Beteiligte Einrichtung: Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Insti…. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Nervous System Diseases. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIA NIH HHS, Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
Background
Commercial genome‐wide genotyping arrays have historically neglected coverage of genetic variation across populations.
Objective
We aimed to create a multi‐ancestry genome‐wide array that would include a wide range of neuro‐specific genetic content to facilitate genetic research in neurological disorders across multiple ancestral groups, fostering diversity and inclusivity in research studies.
Methods
We developed the Illumina NeuroBooster Array (NBA), a custom high‐throughput and cost‐effective platform on a backbone of 1,914,934 variants from the Infinium Global Diversity Array and added custom content comprising 95,273 variants associated with more than 70 neurological conditions or traits, and we further tested its performance on more than 2000 patient samples. This novel platform includes approximately 10,000 tagging variants to facilitate imputation and analyses of neurodegenerative disease–related genome‐wide association study loci across diverse populations.
Results
In this article, we describe NBA's potential as an efficient means for researchers to assess known and novel disease genetic associations in a multi‐ancestry framework. The NBA can identify rare genetic variants and accurately impute more than 15 million common variants across populations. Apart from enabling sample prioritization for further whole‐genome sequencing studies, we envisage that NBA will play a pivotal role in recruitment for interventional studies in the precision medicine space.
Conclusions
From a broader perspective, the NBA serves as a promising means to foster collaborative research endeavors in the field of neurological disorders worldwide. Ultimately, this carefully designed tool is poised to make a substantial contribution to uncovering the genetic etiology underlying these debilitating conditions. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
- Data Tecnica, Washington, District of Columbia, USA.
- Illumina Inc, San Diego, California, USA.
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
ORCID-Profile: Sara Bandres-Ciga, Jeffrey Kim, Mary B Makarious, Hirotaka Iwaki, Katja Lohmann, Edwin Jabbari, Derek Narendra, Claudia Schulte, Huw R Morris, Sonja W Scholz, Henry Houlden, Cornelis Blauwendraat
Förderung
- Intramural NIH HHS
- NIA NIH HHS
- Michael J. Fox Foundation for Parkinson's Research
- NINDS NIH HHS
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Bandres-Ciga, S., Faghri, F., Majounie, E., Koretsky, M. J., Kim, J., Levine, K. S., Leonard, H., Makarious, M. B., Iwaki, H., Crea, P. W., Hernandez, D. G., Arepalli, S., Billingsley, K., Lohmann, K., Klein, C., Lubbe, S. J., Jabbari, E., Saffie-Awad, P., Narendra, D., …, & Global Parkinson's Genetics Program (GP2) and the Center for Alzheimer's and Related Dementias (CARD) (2024). NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations. Movement Disorders, 39(11), 2039-2048. https://doi.org/10.1002/mds.29902
Vancouver
Bandres-Ciga S, Faghri F, Majounie E, Koretsky MJ, Kim J, Levine KS, et al. NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations. Movement Disorders. 2024;39(11):2039-2048. doi:10.1002/mds.29902
BibTeX
@article{BandresCiga2024,
author = {Bandres-Ciga, Sara and Faghri, Faraz and Majounie, Elisa and Koretsky, Mathew J and Kim, Jeffrey and Levine, Kristin S and Leonard, Hampton and Makarious, Mary B and Iwaki, Hirotaka and Crea, Peter Wild and Hernandez, Dena G and Arepalli, Sampath and Billingsley, Kimberley and Lohmann, Katja and Klein, Christine and Lubbe, Steven J and Jabbari, Edwin and Saffie-Awad, Paula and Narendra, Derek and Reyes-Palomares, Armando and Quinn, John P and Schulte, Claudia and Morris, Huw R and Traynor, Bryan J and Scholz, Sonja W and Houlden, Henry and Hardy, John and Dumanis, Sonya and Riley, Ekemini and Blauwendraat, Cornelis and Singleton, Andrew and Nalls, Mike and Jeff, Janina and Vitale, Dan and Global Parkinson's Genetics Program (GP2) and the Center for Alzheimer's and Related Dementias (CARD), Global Parkinson's Genetics Program (GP2) and the Center for Alzheimer's and Related Dementias (CARD)},
title = {NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {11},
pages = {2039--2048},
doi = {10.1002/mds.29902}
}
EUVIMED